How to switch from Lexapro (escitalopram) 10mg to Prozac (fluoxetine)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 29, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Switching from Lexapro (Escitalopram) 10mg to Prozac (Fluoxetine)

Use a cross-taper approach over 1-2 weeks: reduce escitalopram to 5mg daily while starting fluoxetine 10-20mg daily for one week, then discontinue escitalopram completely while continuing fluoxetine. 1, 2

Cross-Taper Protocol

The recommended switching strategy involves gradual cross-tapering rather than abrupt discontinuation or conservative washout periods. 3, 4

Week 1:

  • Reduce escitalopram from 10mg to 5mg (50% reduction) 2
  • Simultaneously start fluoxetine 10-20mg daily 1, 4
  • This overlap period maintains antidepressant coverage while minimizing withdrawal risk 1

Week 2:

  • Discontinue escitalopram completely 2
  • Continue fluoxetine at the same dose 2
  • Fluoxetine can be titrated upward after 4-6 weeks if needed for optimal response 4

Critical Safety Monitoring

Monitor intensively for serotonin syndrome during the overlap period, especially in the first 24-48 hours. 1, 2 Key symptoms include:

  • Tremor, neuromuscular rigidity, hyperreflexia 1
  • Agitation, confusion, mental status changes 1
  • Tachycardia, hyperthermia, diaphoresis 1
  • Diarrhea and sweating 2

The cross-taper approach significantly reduces discontinuation syndrome risk compared to abrupt cessation. 2 Watch for escitalopram withdrawal symptoms including:

  • Dizziness, vertigo, sensory disturbances 1
  • Irritability, anxiety, headache 1
  • Nausea, fatigue, insomnia 1

Rationale for This Approach

Direct or rapid cross-taper switching is well-tolerated between SSRIs and does not require washout periods. 3, 4 The conservative approach with prolonged washout is unnecessary when switching between non-MAOI antidepressants and risks treatment gaps with potential symptom exacerbation. 3

Escitalopram has minimal effect on CYP450 enzymes, reducing drug interaction concerns during the overlap. 1 Fluoxetine's long half-life (4-6 days for fluoxetine, 4-16 days for its active metabolite norfluoxetine) provides built-in protection against discontinuation symptoms once established. 3

Follow-Up Schedule

Contact the patient during weeks 1-2 to assess tolerability and adherence. 2 Schedule a follow-up visit after completing the switch (week 3-4) to evaluate:

  • Therapeutic response 2
  • Adverse effects 2
  • Need for dose adjustment 2

Fluoxetine typically requires 4-8 weeks at therapeutic doses before assessing full efficacy. 5, 6

Common Pitfalls to Avoid

Never abruptly discontinue escitalopram - this significantly increases discontinuation syndrome risk. 2

Do not use conservative washout periods between these SSRIs - this unnecessarily prolongs the switch and risks symptom recurrence. 3, 4

Monitor adherence closely - patients may discontinue one medication without starting the other, leading to relapse. 2

Avoid combining with MAOIs or other serotonergic agents beyond the planned cross-taper period. 2

Special Considerations

For elderly patients or those with hepatic impairment, consider:

  • More gradual cross-taper over 2-3 weeks 2
  • Lower starting dose of fluoxetine (10mg rather than 20mg) 2
  • More frequent monitoring 2

The switch from escitalopram to fluoxetine is appropriate when seeking different pharmacologic properties within the SSRI class, such as fluoxetine's longer half-life or different side effect profile. 7, 6

References

Guideline

Switching from Sertraline to Escitalopram

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Switching from Escitalopram to Sertraline

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Switching and stopping antidepressants.

Australian prescriber, 2016

Research

Switching treatments for complicated depression.

The Journal of clinical psychiatry, 2010

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.